All In Biotech

NDA 206089 · Tolmar

Jatenzo

Testosterone Undecanoate · Oral

Last checked: Nov 19, 2026Latest source record: Sep 12, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Mar 27, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

82

23 Phase 3, 9 recruiting

FAERS reports

563

270 serious, 22 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 13, 2026.

JATENZO (testosterone undecanoate) is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range. Limitations of use: Safety and efficacy of JATENZO in men with “age-related hypogonadism” have not been established. Safety and efficacy of JATENZO in males less than 18 years old have not been established [ see Use in Specific Populations ( 8.4 ) ]. JATENZO (testosterone undecanoate) is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone ( 1 ). Limitations of use: Safety and efficacy of JATENZO in men with “age-related hypogonadism” have not been established ( 1 ) Safety and efficacy of JATENZO in males less than 18 years old have not been established ( 1 , 8.4 ).

Mechanism: Endogenous androgens, including testosterone and dihydrotestosterone (DHT), are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include the growth and maturation of prostate, seminal vesicles, penis and scrotum; the development of male hair distribution, such as facial, pubic, chest and axillary hair; laryngeal enlargement, vocal cord thickening, alterations in body musculature and fat distribution. Male hypogonadism, a clinical syndrome resulting from insufficient secretion of testosterone, has two...

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • JATENZO · TESTOSTERONE UNDECANOATE 237MG · CAPSULE, ORAL · Prescription
  • JATENZO · TESTOSTERONE UNDECANOATE 158MG · CAPSULE, ORAL · Prescription
  • JATENZO · TESTOSTERONE UNDECANOATE 198MG · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Testosterone Undecanoate" as an intervention, any sponsor and status, largest first.

All 82 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use60
  • drug ineffective33
  • fatigue28
  • blood testosterone decreased25
  • headache25
  • therapy interrupted25
  • blood testosterone abnormal22
  • intentional product use issue22
  • product availability issue19
  • polycythaemia16
  • blood pressure increased15
  • asthenia14

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
20051
20061
20093
20106
20112
20129
20135
20144
201512
20167
20175
201822
20198
202019
202146
202229
2023107
2024106
2025100
202669

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Jatenzo (Testosterone Undecanoate)

2024 spending

$7.9M

Beneficiaries

1,758

7,521 claims

Per beneficiary

$4,514

$13.20 per unit

View as table
YearSpending
2020$0
2021$752,675
2022$3,293,190
2023$4,591,544
2024$7,934,922

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 217 on PubMed

Sponsor: Tolmar

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.